Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Drug Investig ; 30(3): 205-9, 2010.
Article in English | MEDLINE | ID: mdl-20155993

ABSTRACT

We report a case of acute-onset, long-lasting cholestasis induced by atorvastatin. This antihyperlipidaemic drug was taken for 40 days by a 72-year-old male as a treatment for his mixed dyslipidaemia. At that point, the patient presented with asthenia, nausea, painless icterus, acholic stools and hyperchromic urine with biochemical analyses showing a dramatic increase in bilirubin (total bilirubin 22 mg/dL; direct bilirubin 21 mg/dL) and alkaline phosphatase (up to 4-fold over the normal level) with less marked increases in transaminases. Liver histology showed a pattern of cholestasis with evident signs of cholangiolitis and damage of the interlobular bile ducts. Serum transaminase and bilirubin levels returned to normal within 5 months after atorvastatin withdrawal while alkaline phosphatase normalized after only 8 months. Scores on both the Maria and Victorino clinical scale for the diagnosis of drug-induced hepatitis and the Naranjo Adverse Drug Reaction Probability Scale indicated that atorvastatin was the probable cause of prolonged cholestasis in this patient. This is a rare case of cholestasis probably caused by atorvastatin and unusually characterized by bile duct damage.


Subject(s)
Anticholesteremic Agents/adverse effects , Bile Ducts/drug effects , Cholangitis/chemically induced , Cholestasis/chemically induced , Heptanoic Acids/adverse effects , Pyrroles/adverse effects , Aged , Anticholesteremic Agents/therapeutic use , Atorvastatin , Bile Ducts/pathology , Cholagogues and Choleretics/therapeutic use , Cholangitis/drug therapy , Cholestasis/drug therapy , Dyslipidemias/drug therapy , Heptanoic Acids/therapeutic use , Humans , Male , Pyrroles/therapeutic use , Ursodeoxycholic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...